Sugi Predict

Sugi Predict / Targets / HASPIN

HASPIN

Serine/threonine-protein kinase haspin · Q8TF76 · HASPIN on Sugi Atlas →

17,820 patent compounds predicted against HASPIN, 9,517 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL445516 SCHEMBL445516 0.48 10/20
SCHEMBL625391 SCHEMBL625391 0.52 9/20
SCHEMBL1594417 SCHEMBL1594417 0.54 8/20
SCHEMBL568019 SCHEMBL568019 0.54 8/20
SCHEMBL624438 SCHEMBL624438 0.44 8/20
SCHEMBL1651489 SCHEMBL1651489 0.43 6/20
SCHEMBL624388 SCHEMBL624388 0.42 6/20
SCHEMBL445029 SCHEMBL445029 0.49 5/20
SCHEMBL625248 SCHEMBL625248 0.43 5/20
SCHEMBL627410 SCHEMBL627410 0.41 5/20
SCHEMBL1450415 SCHEMBL1450415 0.40 5/20
SCHEMBL625458 SCHEMBL625458 0.39 5/20
SCHEMBL668477 SCHEMBL668477 0.72 4/20
SCHEMBL1714205 SCHEMBL1714205 0.53 4/20
SCHEMBL1714207 SCHEMBL1714207 0.53 4/20
SCHEMBL1714077 SCHEMBL1714077 0.52 4/20
SCHEMBL1714080 SCHEMBL1714080 0.52 4/20
SCHEMBL257134 SCHEMBL257134 0.50 4/20
SCHEMBL1714101 SCHEMBL1714101 0.48 4/20
SCHEMBL1714104 SCHEMBL1714104 0.48 4/20

Clinical trials — most relevant to HASPIN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis PHASE4RECRUITING
Proteome-based Immunotherapy of Brain Metastases From Breast Cancer PHASE2/PHASE3UNKNOWN
Proteome-based Immunotherapy of Lung Cancer Brain Metastases PHASE2/PHASE3UNKNOWN
Proteome-based Personalized Immunotherapy of Glioblastoma PHASE2/PHASE3UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
Genetics and Epigenetics of Graves' Orbitopathy nanCOMPLETED
The Role of Maspin in Colorectal Carcinoma, an Immunohistochemical Study nanNOT_YET_RECRUITING
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome nanACTIVE_NOT_RECRUITING
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3) nanUNKNOWN
Normal Serum Adiponectin Levels in Females nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Istmin Levels in Laparoscopik Sleeve Gastrectomy nanCOMPLETED
High-fat Overfeeding, Hepatokines and Appetite Regulation nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
BATokines as Biomarkers of Brown Fat in Humans nanACTIVE_NOT_RECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a HASPIN binder may also engage these)

ProteinNameSimilarity
Q9Z0R0 — 1.000 Q9Z0R0 →
Q2KIP2 — 1.000 Q2KIP2 →
Q9JIC3 — 0.990 Q9JIC3 →
Q5TKR9 — 0.987 Q5TKR9 →
Q9Z0E3 — 0.986 Q9Z0E3 →
DCLRE1A DNA cross-link repair 1A protein 0.986 landscape →
Q66H04 — 0.985 Q66H04 →
Q9BQI7 — 0.984 Q9BQI7 →
Q76N89 — 0.984 Q76N89 →
Q8BLR5 — 0.984 Q8BLR5 →
Q6P1D7 — 0.984 Q6P1D7 →
Q6A037 — 0.984 Q6A037 →
PARG Poly(ADP-ribose) glycohydrolase 0.984 landscape →
USP19 Ubiquitin carboxyl-terminal hydrolase 19 0.984 landscape →
Q9Z1J2 — 0.984 Q9Z1J2 →
Q6P1I6 — 0.984 Q6P1I6 →
Q68UT7 — 0.983 Q68UT7 →
P59110 — 0.983 P59110 →
Q91YK2 — 0.983 Q91YK2 →
Q6NRK3 — 0.983 Q6NRK3 →
Q5ZLE9 — 0.983 Q5ZLE9 →
D3ZAP3 — 0.983 D3ZAP3 →
Q8BJS7 — 0.983 Q8BJS7 →
O70405 — 0.983 O70405 →
Q8BZW2 — 0.983 Q8BZW2 →
A3KMW7 — 0.983 A3KMW7 →
Q61501 — 0.983 Q61501 →
Q3UJD6 — 0.982 Q3UJD6 →
P42335 — 0.982 P42335 →
Q8BZ21 — 0.982 Q8BZ21 →